Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at Los Angeles, California and other locations
- Dates
- study startedcompletion around
- Principal Investigator
- by Elizabeth R. Volkmann, MD, MS

Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCLA
- Elizabeth R. Volkmann, MD, MS
HS Associate Clinical Professor, Medicine. Authored (or co-authored) 123 research publications
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Links
- Merck Clinical Trials Information Plain Language Summary Sign up for this study
- ID
- NCT05270668
- Phase
- Phase 2 research study
- Study Type
- Interventional
- Participants
- Expecting 152 study participants
- Last Updated